About Aedion

Science first.
Institution built to last.

Aedion Therapeutics was founded to translate pioneering dengue science into a globally protected, clinically advanced therapeutic platform.

Founding Purpose

Created to advance an existing body of work.

Aedion Therapeutics was created not to start from zero, but to capture, protect, and advance an existing body of scientific and clinical work within a strong commercial and legal structure. By securing exclusive global rights, centralising know-how, and building a focused regulatory and clinical pathway, Aedion seeks to convert promising science into a durable therapeutic asset.

The company builds on pioneering scientific work established by Professor Max Reynolds and is designed to transform that foundation into a globally protected, clinically advanced therapeutic programme. Aedion combines intellectual property strategy, product standardisation, regulatory planning, and clinical development execution to create a focused infectious disease platform with regional relevance and global ambition.

"Aedion was created not to start from zero, but to capture, protect, and advance an existing body of scientific and clinical work within a strong commercial and legal structure."

Founding Principle · Aedion Therapeutics
Mission
To develop safe, effective, and accessible therapies for dengue and other high-burden viral diseases.
Vision
To become the leading therapeutics company focused on mosquito-borne viral disease.
Founding Purpose
To advance and globalise the pioneering scientific work of Professor Max Reynolds through a dedicated development platform.

The Name

A name that reflects scientific purpose.

The name Aedion is inspired by Aedes — the mosquito genus responsible for dengue transmission — reshaped into a modern biotechnology identity. It signals a close biological connection to dengue while remaining elegant, scalable, and institutionally credible.

Aedion is designed to feel serious, global, and enduring. Appropriate for a company developing regulated therapeutics and building long-term strategic value for investors and partners — not a promotional claim, but a scientific statement of intent.

Aedes  →  Aedion

Etymology

Derived from Aedes aegypti, the primary mosquito vector of dengue. Aedion retains the scientific root while projecting the authority and institutional permanence appropriate for a globally structured therapeutics company.

Scientific Foundation

Grounded in pioneering prior work.

Scientific Origin
Professor Max Reynolds

Aedion Therapeutics is built on the scientific foundation established by Professor Max Reynolds, whose pioneering research programme underpins the VMD55 asset and the company's entire development thesis.

The company's role is to honour that contribution by building the legal, commercial, and clinical infrastructure capable of carrying the science forward — independently, credibly, and at global scale. Aedion recognises the origin of its scientific programme while building an institution that can sustain it far beyond any single contributor.

Brand Pillars

Five principles that define how we operate and communicate.

01
Scientific Credibility
Committed to rigorous, evidence-based development grounded in real science. Every claim is supportable. We earn trust through accuracy, not enthusiasm.
02
Global Stewardship
Rights, know-how, supply, and strategy unified into a professional global structure built for long-term value — not opportunistic positioning.
03
Quiet Ambition
We lead through substance rather than hype. Our brand conveys seriousness, confidence, and purpose earned through scientific rigour and disciplined execution.
04
Regional Relevance, Global Standards
Execution pathways that are practical and regionally informed, while maintaining standards that support international regulatory credibility.
05
Respect for Origin, Focus on Future
We honour the pioneering contribution of Professor Max Reynolds while building an institution capable of carrying the science forward independently.

Aedion communicates as a serious scientific institution. Measured. Confident. Purposeful.

Investment Case

Leadership

The team building Aedion.

Aedion Therapeutics is led by a board that brings together the scientific origin of the programme with corporate leadership, capital markets and commercial experience across Australia, New Zealand, South-East Asia and the United States.

JH
Chairman
James Henderson
Chairman of Transocean Group and ProstaCare, with more than 35 years’ experience in corporate strategy, capital raising and commercial negotiation. Former Chairman of Anteo Diagnostics and adviser to Guidance Interactive Healthcare (GlucoBoy), with a track record across public and private company leadership.
SC
Managing Director
Stuart Cairns
Managing Director of Aedion Therapeutics and principal of Cairns & Company. An investment banker with more than 35 years’ experience commercialising therapeutics and life-science IP across New Zealand, Australia, South-East Asia and the United States.
MR
Scientific Director
Prof. Max Reynolds
Chemist and microbiologist with more than five decades in scientific research and product development, and originator of the research programme behind VMD55. Former lecturer at Griffith University and Director of the Program in Australasia Botanical Medicine for Population Health.
DB
Non-Executive Director
David Begley
More than 30 years in C-level and senior consulting roles with some of the world’s largest companies, across mining, oil and gas, manufacturing and personal care. Extensive strategic and business planning experience at board and executive level; has planned and led business start-ups, including a successful IPO.

Advancing dengue therapeutics with global structure and scientific rigour.

Aedion Therapeutics is accepting enquiries from institutional investors, strategic partners, and specialist healthcare funders.

Request Overview Flyer Data Room Access